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Abstract 
Amphiphysin, a neuronal protein first identified in chicken synaptic membranes, is the autoantigen of Stiff-Man Syndrome (SMS) associated with 
breast cancer. We have now cloned human amphiphysin and found the N- and C-terminal domains of the protein to be highly conserved between 
chicken and human. Patient autoantibodies have a distinct pattern of reactivity with amphiphysin, and the dominant autoepitope is located in its 
C-terminal region, which contains an SH3 domain. Portions of chicken and human amphiphysin are also homologous to portions of Rvs167 and 
Rvsl61, two yeast proteins which are involved in cell entry into stationary phase upon exposure to unfavourable growth conditions. 
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1. Introduction 
Stiff-Man Syndrome (SMS) is a rare neurological dis- 
ease characterized by rigidity of the body musculature 
with superimposed painful spasms [l&4]. SMS is one of 
the few human diseases for which evidence of an autoim- 
mune process directed against CNS neuronal antigens 
has been found. High titer antibodies directed against 
neuronal autoantigens are found both in the serum and 
in the cerebrospinal fluid of the majority of SMS patients 
t51. 
Two main targets of humoral autoimmunity have been 
identified in two populations of SMS patients which have 
similar neurological characteristics but different associ- 
ated conditions. In 50-60% of the cases, autoantibodies 
are primarily directed against the GABA-synthesizing 
enzyme glutamic acid decarboxylase (GAD). In these 
patients, insulin-dependent diabetes mellitus and other 
organ-specific autoimmune diseases are frequently pres- 
ent [5-71. 
In five of the more than 100 cases of SMS patients 
whose sera we have tested, autoantibodies are directed 
against another neuronal protein of 128 kDa [8]. This 
protein was recently identified as amphiphysin [9], a syn- 
aptic vesicle-associated protein originally cloned from 
chicken brain [lo]. Strikingly, all five patients with am- 
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Abbreviations: a.a., amino acid; cAmph, chicken amphiphysin; CNS, 
central nervous system; GAD, glutamic acid decarboxylase; hAmph, 
human amphiphysin; PAGE, polyacrylamide gel electrophoresis; PCR, 
polymerase chain reaction; SMS, Stiff-Man Syndrome. 
phiphysin autoimmunity are women with breast cancer. 
In fact, in two of these patients, an infiltrating ductal 
adenocarcinoma of the breast was searched for, and 
found, only after the identification of the anti-am- 
phiphysin antibodies ([8] and our most recent case (pa- 
tient 1 of this study - see section 2)). A remission of the 
neurological symptoms was documented in three of the 
five patients after removal of the cancer and steroid ther- 
apy ([8,9,1 I] and this study (Dr. M. Myers, Jackson, MI, 
personal communication)) supporting the hypothesis 
that the condition results from a functional rather than 
structural damage of the CNS. Other cases of SMS asso- 
ciated with cancer have been described [12,13]. These 
findings raise the possibility that in some cases SMS may 
have an autoimmune paraneoplastic origin. As in the 
case of autoantigens of other autoimmune paraneoplas- 
tic diseases of the CNS, as well as of GAD, amphiphysin 
is an intracellular protein and the link between humoral 
autoimmunity directed against the autoantigen and the 
clinical symptoms remains to be explained. 
In other neurological autoimmune paraneoplastic 
conditions, expression of the neuronal autoantigen in the 
tumor was reported [14,15]. It was proposed that the 
ectopic expression of the brain antigen by cancer cells 
may trigger the autoimmune response [16]. In some 
cases, the autoantigen is thought to play a role in neo- 
plastic growth [17]. As a first step to investigate mecha- 
nisms of amphiphysin autoimmunity and a possible role 
of amphiphysin in the biology of human breast cancer, 
we have now cloned human amphiphysin and mapped 
the autoepitopes. By Western blotting, a stereotypic hu- 
moral autoimmune response to amphiphysin was de- 
tected similarly to what we have previously shown for 
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GAD autoimmunity in SMS [lS]. The region of am- 
phiphysin most highly conserved -between chicken and 
human is also similar to two yeast proteins, Rvs161 [19] 
and Rvs167 [20] which are implicated in the transition 
from exponential cell growth to stationary phase upon 
exposure to nutrient starvation. The similarity of am- 
phiphysin to yeast proteins which participate in station- 
ary phase adaptation suggests the possibility that am- 
phiphysin, or a closely related protein, has a role in the 
biology of breast cancer. 
2. Materials and methods 
2.1. Human sera 
A new serum, belonging to a 75-year-old woman (patient I) with 
SMS was referred to us (Dr. S. Songcharden, Dr. M. Myers, Jackson, 
MI) to be tested for the presence of anti-neuronal antibodies. The 
detection of anti-amphiphysin autoantibodies prompted a search for an 
occult breast cancer. A small ductal adenocarcinoma was found and 
surgically removed. Sera from four patients with SMS and breast can- 
cer were previously described (patients 2-5) [8,9]. Control sera were 
from healthy subjects. 
2.2. DNA manipulations 
Molecular biological procedures were performed according to stand- 
ard protocols [21]. Synthetic oligonucleotides were synthesized (Keck 
Biotechnology Resource Laboratory, Yale University) in order to am- 
plify via PCR from a ilZAP chicken brain cDNA library (courtesy of 
M. Bartkiewicz and R. Baron, Yale University) two fragments of 
chicken amphiphysin [IO] corresponding to nucleotides 75-341 and 
777-1384 (nt75-341, nt777-1384). [a.-32P]dATP was incorporated into 
purified PCR products via primer-direct labeling as described by Bogue 
[22] and used as probes at 2 x106 cpm/ml for Northern blots and IO5 
cpm/ml for library screening under relatively high stringency conditions 
(hybridization - 50% formamide, 6 x SSC, 0.1% SDS, 2 x Denhardt’s, 
100 mg/ml salmon sperm DNA, 37”C, 20 h; wash ~ 2 x SSC, 0.05% 
SDS, 45’C). 
1.5 x IO6 plaques of a /2gtll human cerebellar cDNA library (ran- 
dom- and oligo(dT)-primed; Clontech, Palo Alto, CA) were screened 
with nt777-1384. Phage cDNA inserts of positive clones were purified 
and sequenced [23]. Sequence data, hydrophilicity, and antigenicity 
profiles were compiled and analyzed using MacVector (IBI Ltd., Cam- 
bridge, UK) and MacDNASIS Pro (Hitachi, San Bruno, CA) software. 
BESTFIT [24], BLAST [25] and PlLEUP [26] analyses were programs 
of the Genetics Computer Group (Madison, WI). Secondary structure 
predictions were done by the Self Optimized Prediction Method [27]. 
2.3. Preparation offision proteins 
The fragment corresponding to nt 89-2377 of clone 22-2 was ligated 
into SmaI-.EcoRI sites of pGEX-2T vector (Pharmacia, Piscataway, 
NJ) to generate a glutathione S-transferase (GST)/full-length human 
amphiphysin fusion protein. Clone 22-2 was used as a cDNA template 
in PCR reactions with Vent, DNA polymerase (New England Biolabs, 
Beverly, MA), to obtain the amphiphysin fragments encoding amino 
acids (a.a) I-161, 132~291,262-435,41 l-581, and 545-695 (designated 
I-V, see Fig. 4A). SmaI and EcoRI sites were added to 5’ and 3’ ends 
of the fragments respectively to allow unidirectional subcloning into the 
polylinker region of pGEX-2T. The sequences of all GST-amphiphysin 
fusion constructs were confirmed by DNA sequencing. The fusion 
proteins were produced in DH5a cells and purified on a glutathione- 
Sepharose 4B column (Pharmacia, Piscataway, NJ) essentially as de- 
scribed [28]. Constructs yielded recombinant proteins composed of 
GST (-28 kDa) fused to the N-terminus of the corresponding am- 
phiphysin fragment. 
2.4. Miscellaneous procedures 
SDS-PAGE of 5-16% gradient gels and Western blotting were per- 
formed essentially as described by Laemmli [29] and Towbin [30], re- 
spectively. Western blots with patient sera was performed as described 
[IQ. 
A serum directed against human amphiphysin (CD6) was obtained 
by injecting a rabbit with GST-human amphiphysin fusion protein (I 
mg) which had been purified on a GTH-Sepharose column followed by 
preparative SDS-PAGE. 
3. Results and discussion 
In order to clone human amphiphysin, two fragments 
of chicken amphiphysin [lo], nt75-341 and nt777-1384, 
encoding for amino acids (a.a.) 1-81 and 228430, re- 
spectively, were generated and tested for reactivity in 
Northern blot before proceeding to screen a Agtll 
human cerebellar cDNA library. As expected, both frag- 
ments hybridized very strongly to a band of approxi- 
mately 4.5 kb in chicken brain poly(A)’ mRNA. They 
also labeled more weakly a band of similar size when 
tested under high stringency conditions on rat brain 
polyA+ mRNA (data not shown). 
The nt777-1384, corresponding to the central region 
of chicken amphiphysin [lo], was then used as a probe 
to screen 1.5 x lo6 plaques of a Lgtll human cerebellar 
cDNA library. Eighteen positive clones were isolated, 
four of which (designated 22-2, 24, 27 and 34) were also 
positive when hybridized with the chicken fragment 
nt75-34 1, which encompassed the N-terminal. Sequence 
analysis revealed that clone 22-2 contained an -2.4 kb 
insert, which had an open reading frame of 2088 nt (nt 
111-2198) encoding a protein of 695 a.a. (Fig. 1, top 
line). The nucleotide sequence ncoding the putative pro- 
tein was 73% identical to the nucleotide sequence of 
chicken amphiphysin. The sequence surrounding the 
first ATG (gcagccatgg), at position 111 of clone 22-2, 
conformed very well to the initiation consensus equence 
as defined by Kozak [3 13. No polyadenylation signal was 
detected at the 3’ end of the clone (nt2199-2377). How- 
ever, a stretch of 10 A’s was found (nt2365-2374), sug- 
gesting that internal annealing of the oligo(dT) primer 
occurred at this site. Clones 24, 27 and 34 were identical 
in sequence to smaller portions of clone 22-2 except for 
clone 27 which differed by 20 nucleotides in the 5’ non- 
coding region. Whether this represents a cloning artifact 
or evidence of a transcript alternatively spliced at the 5’ 
region, remains to be determined. 
The predicted molecular weight (76.25 kDa) of the 
protein encoded by clone 22-2 was considerably smaller 
than the apparent molecular weight of rat amphiphysin 
in SDS-PAGE gels which is approximately 128 kDa 
[8,9]. However, a similar aberrant electrophoretic mobil- 
ity was previously reported for chicken amphiphysin 
[lo]. Injection of a GST-human amphiphysin fusion pro- 
tein in rabbits elicited the production of antibodies which 
reacted very strongly with the 128 kDa antigen recog- 
nized by patient sera in brain tissue (Fig. 2). Addition- 
ally, the GST-fusion protein had an apparent molecular 
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Fig. 1. Amino acid sequence alignment of human amphiphysin (hAmph) with chicken amphiphysin (cAmph) and the yeast proteins, Rvs167 and 
Rvsl61. Amino acids are shown in single letter code and identity with the human sequence at a given position is boxed. First the sequences of the 
two amphiphysins and of Rvs167 were aligned to each other using the program PILEUP. The sequence of Rvs 161 was then compiled with the other 
three sequences according to its alignment with Rvs 167. The complete cDNA sequence of hAmph (clone 22-2) is available from GenBank under 
accession number U076 16. 
weight of approximately 160 kDa, of which only about 
28 kDa could be attributed to GST (see figure 4B, panel 
CB, lane H). Finally, when the human and chicken se- 
quences were aligned, the N- and C-termini of the two 
molecules were in precise register (Fig. 1, top two lines). 
In conclusion, the above data indicates that we had iso- 
lated a full-length clone of human amphiphysin. 
A comparison of the a.a. sequences of human and 
chicken amphiphysin [lo] revealed a high degree of sim- 
ilarity with the exception of a region of approximately 
180 a.a. in the second half of the molecules (Fig. 1 and 
Fig. 3A domain C). Overall the two proteins are 75% 
identical and 84% similar at the a.a. level. As was previ- 
ously reported for chicken amphiphysin [lo], the human 
protein is very hydrophilic, has an acidic pI of 4.4, and 
contains many putative phosphorylation sites for protein 
kinases A and C and for casein kinase II. The first 
Fig. 2. The same protein band from rat brain is recognized by a rabbit 
antibody raised against human amphiphysin and by the serum of a 
patient with SMS and breast cancer. A total rat brain homogenate was 
subjected to SDS-PAGE and Western blotting as described in section 
2. Sera used for western blotting are as follows: NHS = serum from 
control human subject, 11500; Pt 2 = serum from patient with SMS and 
breast cancer, 11500; pre-CD6 = pre-immune rabbit serum 1150; 
CD6 = serum from rabbit immunized with human amphiphysin, 1150. 
Molecular weight standards are indicated on the left. 
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Fig. 3. (A) Domain diagram of amphiphysins and related yeast proteins 
suggested by blocks of a.a. similarity. The borders of the domains were 
based on sequence alignment and are drawn to scale (shown). (B) The 
last 60 a.a. of hAmph was aligned with the SH3 domains of human src 
(hsrc [42]), yeast abpl (yabpl [43]), human GRB2 (hGRB2 [35]), droso- 
phila drk gene product (Drk [44]), human spectrin a chain (hspec [45]) 
and Rvs167 [20] using the PILEUP program. N and C represent N- and 
C-terminal SH3 domains where applicable. Numbers to the right of the 
sequence indicate the position of the last a.a. shown in the sequence of 
the protein and a c) indicates a terminal a.a. Dashes indicate a.a. that 
are identical with human amphiphysin and periods represent gaps. A 
consensus SH3 sequence was constructed whenever the same a.a. was 
conserved in at least four of the sequences listed and an alignment of 
this sequence with amphiphysin is shown as was done by Bauer et al, 
[20]. G and P in bold refer to highly conserved residues and * indicates 
G,,, and P,, of GRB2 (see text). 
400 a.a. (domains A+B) are 91% identical and the last 
100 a.a. (domain D) are 67% identical. 
Although the C domains are only 40% identical, in this 
region the a.a. profile of chicken and human am- 
phiphysin is strikingly similar with a predominance of 
alanine and glutamate. A proline-rich region between 
amino acids 263-277 in domain B, which contains puta- 
tive binding sequences for src-homology (SH3) domains 
[32,33] is also highly conserved. SH3 domains are protien 
modules of about 60 a.a. that are found in many signal- 
ing and cytoskeletal proteins [34]. Domain C of chicken 
amphiphysin was reported to contain the only hydro- 
phobic stretch (a.a. 478499) of the molecule, although 
this stretch does not appear to form a transmembrane 
region [9,10]. A short a.a. sequence with similar hydro- 
phobic properties is present in domain C of human am- 
phiphysin (a.a. 468480). 
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Domain D, present in both human and chicken am- 
phiphysin, comprises the C-terminal 100 a.a. and is ap- 
proximately 30% identical with SH3 domains from a 
variety of proteins in its last 60 a.a.(Fig. 3B). Secondary 
structure analysis of this domain predicted the presence 
ofj?-sheets between a.a. 648-652 and 664-668, in agree- 
ment with the known crystal structure of SH3 domains 
[34]. The gaps needed to align the SH3 domain consensus 
with amphiphysin are in regions where there is consider- 
able variability between SH3 containing proteins [34]. 
Furthermore, the putative SH3 domain of amphiphysin 
includes a glycine (position 684) and a proline (position 
687), (Fig. 3B - in bold) which are conserved in all SH3 
domains listed. In particular, mutations of Gzo3 or P,,of 
GRB2 (Fig. 3B, asterisks) result in an inability of GRB2 
to bind other proteins via its C-terminal and N-terminal 
SH3 domains, respectively [28,35] and correspond to loss 
of function mutants in the GRB2 homologue, sem-5 [36]. 
The availability of the human amphiphysin clone al- 
lowed us to start investigating mechanisms of autoimmu- 
nity to amphiphysin in SMS associated with breast can- 
cer. Neurological symptoms of SMS patients with either 
GAD or amphiphysin autoimmunity are similar [8,9]. 
This observation, together with the intracellular localiza- 
tion of both GAD and amphiphysin, suggest that au- 
toantibodies are closely related to, but not responsible 
for, the disease. In the case of GAD autoimmunity, we 
have shown a common autoreactive pattern of SMS au- 
toantibodies. In all cases, autoantibodies predominantly 
recognize a single epitope in the C-terminal region of 
GAD65 [18]. To determine whether the humoral autoim- 
mune response to amphiphysin was stereotyped, sera 
from all 5 breast cancer patients with SMS as well as 
control sera were tested by western blotting against five 
overlapping amphiphysin fragments expressed as GST- 
fusion proteins (Fig. 4A). 
As shown in Fig. 4B, autoantibodies from all 5 pa- 
Table 1 
Comparison of domain A of amphiphysin related proteins 
Chicken Rvs 167 Rvs I61 
amphiphysin l-272 l-265 
l-261 
Human 
amphiphysin 
l-261 95.4 (97.7) 27.3 (48.7) 25.2 (49.2) 
Chicken 
amphiphysin 
l-261 _ 26.5 (48.7) 22.8 (46.8) 
Rvs 167 
l-272 _ 26.9 (51.9) 
Percent identities and similarities (in brackets) of the a.a. sequence of 
domains A (numbers represent the boundaries of each domain A, refer 
to Fig. 3) of the indicated proteins as obtained using the BESTFIT 
program. 
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Fig. 4. Similar pattern of reactivity of patient sera with the C-terminal 
portion of human amphiphysin. (A) Schematic diagram of full-length 
human amphiphysin (H) and of its fragments (I-V) which were tested 
for reactivity with human sera. Boundaries of the fragments are indi- 
cated by a.a. numbers. (B) GST-fusion proteins of the constructs shown 
in A were subjected to SDS-PAGE and either Coomassie blue stained 
(CB) or Western blotted as described in section 2. The blots were 
reacted with either sera ofpatients with SMS and breast cancer (Pt l-5), 
normal human sera (NHS), or CD6 (rabbit) sera at l/500 as indicated. 
Approximately 113 of the amount loaded in the gel for panel CB was 
used for the Western blot analysis. These results are representative of 
at least 3 separate experiments. Molecular weight standards are indi- 
cated on the left. All fusion proteins (I-V) run between 45 and 66 kDa. 
The 80 kDa band seen in lane II (panel CB) was a protein from the host 
bacteria that was not related to the specific fusion protein, and never 
reacted with the antibodies. 
II 
tients were directed primarily, although not exclusively, 
against the amphiphysin C-terminal fragment (frag- 
ment V). Autoantibodies from patients 4 and 5 also rec- 
ognized, but to a lower extent, fragment II. In contrast, 
a rabbit serum (CD6), raised against human am- 
phiphysin, recognized primarily the central fragment III, 
suggesting that the stereotypic pattern of antibody reac- 
tivity against the C-terminal fragment is typical of the 
disease and does not simply reflect an unusually high 
antigenicity of this domain. We have previously reported 
that the neurological symptoms of SMS improve after 
removal of the cancer [8]. Interestingly, a similar im- 
provement was noticed for the two patients identified 
after our original report (Dr. H.-M. Meinck, Heidelberg, 
Germany and Dr. M. Myers, Jackson, MI, personal 
communication). This observation strengthens the con- 
cept that SMS associated with breast cancer is an au- 
toimmune paraneoplastic disease. 
Since amphiphysin is a synaptic vesicle-associated pro- 
tein [lo], its relation to a disease involving abnormal 
synaptic function is plausible. On the other hand, the 
connection between amphiphysin and breast cancer has 
been more elusive. A possible clue concerning this con- 
nection comes from an interesting homology we have 
identified by searching protein databases for a.a se- 
quences imilar to the regions of amphiphysin conserved 
between human and chicken. The conserved N-terminal 
region of amphiphysin has considerable homology to 
Rvs167 [20] and Rvs161 [19], two yeast proteins which 
were cloned by isolating mutants with a reduced viability 
to nutrient starvation (rvs). The alignment of Rvs167 
and Rvs161 with human and chicken amphiphysin (Fig. 
1) suggests a domain model of the four proteins shown 
in Fig. 3A. Domain A is shared by all four proteins and 
in all four has a high a-helix potential. The similarities 
among the various domains A are indicated in Table 1. 
Rvs 16 1 is comprised exclusively of this domain, whereas 
Rvs167 shares an additional region of similarity with 
amphiphysin in domain D. Domain D of Rvs167 was 
previously shown to contain an SH3 domain [20]. Do- 
main X of Rvs167 was defined as a GPA-rich region 
because of its high content in glycine, proline and alan- 
ine. While this region is substantially shorter than the 
central region of amphiphysin, it shares some features of 
both domains B and C of human and chicken am- 
phiphysin which are rich in proline and alanine, respec- 
tively. These considerations uggest hat Rvs167 is the 
yeast homologue of amphiphysin. While amphiphysin 
has been shown to have a very restricted tissue distribu- 
tion (brain, endocrine tissues and testis)[9,10], the pres- 
ence of a homologue in yeast strongly suggests that am- 
phiphysin homologues are present in all cells. 
The phenotype of RVSl67 and RVS161 mutant cells 
is associated with abnormal morphology and alterations 
in the peripheral cytoskeleton. Cells appear to be unable 
to adapt to unfavorable growth conditions by an im- 
78 
paired link between the mechanisms which control cell 
proliferation and those which allow the cell to undergo 
stationary phase adaptation. Mutations of either one of 
the two genes produce a similar phenotype [19,20] and 
are suppressed by the same set of genes [37], indicating 
that they act in the same pathway. The function of am- 
phiphysin in the nervous system remains to be eluci- 
dated. Amphiphysin was reported to be a synaptic vesi- 
cle-associated protein, although it is not enriched in these 
organelles [lo]. The homology of amphiphysin to the two 
Rvs yeast proteins suggests a function of amphiphysin in 
controlling the properties of the membrane associated 
cytoskeleton and offers the possibility of using yeast ge- 
netics to further investigate the function of the protein. 
It was proposed that neurological autoimmune para- 
neoplastic syndrome are triggered by the ectopic expres- 
sion in the neoplastic tissues of a neuronal protein or a 
protein antigenically related to it, which then becomes an 
autoantigen [16,38]. The homology of amphiphysin to 
yeast proteins which have been shown to participate in 
the cell adaptation to stationary phase raises the possibil- 
ity that amphiphysin or some related protein may be 
directly involved in at least some form of breast cancer. 
There is evidence to suggest hat proteins of the periph- 
eral cell cytoskeleton may be directly involved in the 
pathogenesis of some forms of cancer [39-41] In the 
breast cancer tissue of SMS patients which have been 
investigated, amphiphysin immunoreactivity was not de- 
tected using patient autoantibodies [8]. However, one 
should consider the possibility that the T-cell triggering 
autoepitope might belong to an amphiphysin-related 
molecule which similarly to Rvsl61, contains only do- 
main A. This protein would not be recognized by patient 
autoantibodies which we have now shown to be primar- 
ily directed against the C-terminus of amphiphysin. We 
note that Nova, another autoantigen of a paraneoplastic 
neurological autoimmune disorder, is a neuronal protein 
expressed in a truncated form (which does not include 
the dominant C-terminal autoepitope for humoral au- 
toimmunity) in the neoplastic tissue [17]. 
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